Siolta Therapeutics
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products using its Precision Symbiotics Platform to prevent and treat inflammatory diseases, with lead program STMC-103H in Phase 2 trials for allergic disease prevention in at-risk infants.
- Company typePrivate
- Founded2016
- HeadquartersSan Carlos, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Siolta Therapeutics does
Siolta Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Carlos, California, that develops live biotherapeutic products (LBPs) targeting the microbiome to prevent and treat inflammatory diseases. Its lead program, STMC-103H, is a mixed-strain bacterial consortium in Phase 2 development for prevention of atopic dermatitis, food allergy, and allergic asthma in at-risk infants, having received FDA Fast Track Designation and reported a 64% reduction in atopic dermatitis risk in the ADORED study in November 2025. Two additional programs are in preclinical development: STMC-105 for recurrent bacterial vaginosis and STMC-106 for prevention of necrotizing enterocolitis in preterm infants.
The company's discovery and manufacturing engine is its proprietary Precision Symbiotics Platform, which integrates machine learning, network analysis, high-resolution clinical microbiome data, anaerobic microbiology, and in-house GMP manufacturing to rationally design mixed-species consortia. This platform is supported by a proprietary human microbiota biobank, a portfolio of 9 issued and 29 pending patents, and ongoing NIH SBIR-funded manufacturing innovation. Siolta has assembled an advisory team that includes former FDA Chief Counsel Peter Hutt, Harvard Medical School allergy KOL Joshua Boyce, and the late Gilead Chairman John Martin, alongside founders Susan Lynch (UCSF) and CEO Nikole Kimes.
Siolta is currently pre-revenue and plans to commercialize through traditional pharmaceutical channels (hospital and specialty pharmacies, healthcare provider offices) upon regulatory approval. To date the company has raised approximately $42 million in disclosed equity funding across a $30M Series B (September 2020, led by Khosla Ventures) and a $12M Series C (March 2024), supplemented by multiple NIH SBIR awards and a Bill & Melinda Gates Foundation grant. The company operates with 1-10 employees inside MBC Bio Labs in San Carlos.
Siolta Therapeutics firmographics
Firmographics- Name
- Siolta Therapeutics
- Legal name
- Siolta Therapeutics
- Website
- https://sioltatherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Siolta Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products using its Precision Symbiotics Platform to prevent and treat inflammatory diseases, with lead program STMC-103H in Phase 2 trials for allergic disease prevention in at-risk infants.
- Ownership category
- akta.pro rank
Siolta Therapeutics industry classification
Industry- Product category
- Microbiome-based Live Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Live Biotherapeutic Products (LBPs) (HLAAAFAA)
- akta.pro secondary industry
- Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
Keywords
Where Siolta Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Siolta Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Live Biotherapeutic Products: Pre-revenue clinical-stage company developing live biotherapeutic products for prevention and treatment of diseases including atopic diseases, bacterial vaginosis, and necrotizing enterocolitis. Revenue will be generated from product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Siolta Therapeutics product offering
Product offeringCore offering
Siolta Therapeutics develops rationally designed, mixed-strain live biotherapeutic products (LBPs) that target the metabolic and immunological roots of inflammatory and allergic diseases rather than their symptoms. Using its proprietary Precision Symbiotics Platform and in-house cGMP manufacturing, the company advances candidates such as STMC-103H (lead, Phase 2 for atopic disease prevention), STMC-105 (recurrent bacterial vaginosis), and STMC-106 (necrotizing enterocolitis) through FDA-approved clinical pathways.
Product overview
Siolta Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of live biotherapeutic products (LBPs) using its proprietary Precision Symbiotics Platform™. The platform integrates machine learning, bioinformatics, anaerobic microbiology, and in-house GMP manufacturing capabilities to develop mixed-strain bacterial consortia. The company's lead product STMC-103H is in Phase 2 clinical trials for allergic disease prevention, while STMC-105 targets recurrent bacterial vaginosis and STMC-106 targets necrotizing enterocolitis in preterm infants, both in preclinical stages.
Differentiator
Problem solved
Functional benefit
Products and services
- STMC-103H A live biotherapeutic containing a carefully selected mix of beneficial bacteria designed to correct pro-allergic immune development in infants. Currently in Phase 2 clinical trials for the prevention of atopic dermatitis, food allergy, and allergic asthma, with FDA Fast Track Designation and a demonstrated 64% reduction in atopic dermatitis risk in the Phase 2 ADORED study.
- STMC-105 A vaginal bacterial consortium live biotherapeutic designed to provide resilience from vaginal microbiota disruption, opportunistic pathogen colonization, and recurrence of bacterial vaginosis. Currently in preclinical development for women of reproductive age.
- STMC-106 A mixed-strain live biotherapeutic designed to colonize the preterm infant gut with protective, infant-derived bacteria to reduce pathogen colonization, reinforce epithelial development, and reduce inflammation for prevention of necrotizing enterocolitis (NEC). Currently in preclinical development.
Quantifiable outcome
- 64% reduction in atopic dermatitis risk among infants who completed a year of treatment
- +3 more outcomes
Companies that use Siolta Therapeutics
Customer profileSegments3 records
Ideal customer profiles1 record
Siolta Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Siolta Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- CowellnexcoreEntered into a joint research agreement in January 2025 to collaborate on microbiome therapeutic development.
- NexilicocoreCollaboration agreement signed in September 2024 to address necrotizing enterocolitis using combined expertise in microbiome-based therapeutics.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Siolta Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Siolta Therapeutics social profiles
Digital presenceSiolta Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Siolta Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Siolta Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Siolta Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Siolta Therapeutics
What does Siolta Therapeutics do?
Siolta Therapeutics develops rationally designed, mixed-strain live biotherapeutic products (LBPs) that target the metabolic and immunological roots of inflammatory and allergic diseases rather than their symptoms. Using its proprietary Precision Symbiotics Platform and in-house cGMP manufacturing, the company advances candidates such as STMC-103H (lead, Phase 2 for atopic disease prevention), STMC-105 (recurrent bacterial vaginosis), and STMC-106 (necrotizing enterocolitis) through FDA-approved clinical pathways.
Is Siolta Therapeutics a public or private company?
Siolta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Siolta Therapeutics founded?
Siolta Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Siolta Therapeutics based?
Siolta Therapeutics is headquartered in San Carlos, United States, in the North America region.
How does Siolta Therapeutics make money?
One revenue line is on record: live Biotherapeutic Products.
Does Siolta Therapeutics have an API?
No public API is recorded for Siolta Therapeutics.
What industry is Siolta Therapeutics in?
Siolta Therapeutics's product category is Microbiome-based Live Biotherapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.